SCHEMBL2595689

SCHEMBL2595689

CC(Oc1cccc2c1c1c(C(N)=O)cccc1n2Cc1ccccc1)C(=O)O

nearest known ligand 0.66

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 17/20 0.66
PLA2G10 O15496 5/20 0.63
PLA2G2E Q9NZK7 4/20 0.63
PLA2G2F Q9BZM2 3/20 0.63
PLA2G2D Q9UNK4 3/20 0.63
PLA2G1B P04054 3/20 0.63
PLA2G5 P39877 3/20 0.63
KMT2A Q03164 1/20 0.46
PLA2G6 O60733 1/20 0.44
PLA2G2C Q5R387 1/20 0.44
PLA2G12B Q9BX93 1/20 0.44
PLA2G12A Q9BZM1 1/20 0.44
PLA2G3 Q9NZ20 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7968794 0.91 PLA2G2A (0.56) PLA2G2APLA2G10PLA2G2EPLA2G2FPLA2G2D
SCHEMBL27206879 0.90 PLA2G2A (0.54) PLA2G2APLA2G10PLA2G2EPLA2G2FPLA2G2D
SCHEMBL818166 0.89 PLA2G2A (0.54) PLA2G2APLA2G10PLA2G2EPLA2G2FPLA2G2D
SCHEMBL29862552 0.89 PLA2G2A (0.54) PLA2G2APLA2G10PLA2G2EPLA2G2FPLA2G2D
SCHEMBL27844984 0.84 PLA2G2A (0.49) PLA2G2APLA2G10PLA2G2EPLA2G2FPLA2G2D
SCHEMBL7967865 0.83 PLA2G2A (0.51) PLA2G2APLA2G10PLA2G2EPLA2G2FPLA2G2D
SCHEMBL8575181 0.83 PLA2G2A (0.46) PLA2G2APLA2G10PLA2G2EPLA2G2FPLA2G2D
SCHEMBL14941577 0.82 PLA2G2A (0.46) PLA2G2APLA2G10PLA2G2EPLA2G2FPLA2G2D
SCHEMBL3257517 0.82 PLA2G2A (0.46) PLA2G2APLA2G10PLA2G2EPLA2G2FPLA2G2D
SCHEMBL8542255 0.82 PLA2G2A (0.46) PLA2G2APLA2G10PLA2G2EPLA2G2FPLA2G2D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013067579-A1 ADIPOSITY-MODULATING MOLECULES AND USES THEREFOR THE UNIVERSITY OF QUEENSLAND (AU) 2013-05-16 WO disclosed
WO-2011137390-A1 TREATMENT OF MAJOR ADVERSE CARDIAC EVENTS AND ACUTE CORONARY SYNDROME IN DIABETIC PATIENTS USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITOR OR SPLA2 INHIBITOR COMBINATION THERAPIES ANTHERA PHARMACEUTICALS, INC. (US) 2011-11-03 WO disclosed